|  |  |  |
| --- | --- | --- |
|  | Paper 1  *Genetic variation in SLC5A2 mimicking SGLT2-inhibition and risk of* *cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose* | Paper 2  *SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type* |
| Exposure | *SLC5A2* genetic variation | SGLT2-inhibitor treatment |
| Endpoints | Heart failure  Myocardial infarction  Ischemic heart disease  Ischemic stroke  Cardiovascular mortality  All-cause mortality | Change in:  Total cholesterol LDL cholesterol  HDL cholesterol  Triglycerides |
| Materials | CCHS: N = 10,344  CGPS: N = 102,368  UK Biobank: N = 488,687  FinnGen: N = 342,499 | 60 randomized controlled trials, including 147,130 individuals |
| Methods | Survival analysis  Observational analysis  Mediation analysis | Meta-analysis |